Tests vedolizumab with transplant drugs to prevent graft versus host disease
Tests vedolizumab with cyclophosphamide and tacrolimus in adults receiving blood stem cell transplants.
Key facts
- Who runs it
- City of Hope Medical Center
- Where
- Duarte, United StatesSee the site
- Trial code
- Registry title
- Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 35 people, planned
- Started
- 18 Apr 2025
- Expected to end
- 15 Oct 2028
- Type of study
- Interventional
- Treatments tested
- Allogeneic Hematopoietic Stem Cell Transplantation
- Biospecimen Collection
- Bone Marrow Biopsy
- Computed Tomography
- Cyclophosphamide
- Echocardiography
- Fludarabine
- Melphalan
- Multigated Acquisition Scan
- Questionnaire Administration
- Tacrolimus
- Vedolizumab
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with certain blood cancers who will have a stem cell transplant from a fully matched donor. It tests a drug combination to prevent graft-versus-host disease.
- Age
- 18 to 80 years. People over 70 must have Karnofsky performance status of at least 80 and HCT-CI of 2 or less.
- Sex
- All sexes can join.
- Disease stage
- Acute myeloid or acute lymphoblastic leukemia in complete remission with bone marrow blasts under 5%; myelodysplastic syndrome with blasts under 10%; myeloproliferative neoplasm other than myelofibrosis needing transplant; or chronic myelomonocytic leukemia. Must be able to have a transplant from an 8/8 compatible related or unrelated donor.
- Earlier treatment
- No earlier allogeneic stem cell transplant. No chemotherapy, radiation, biological therapy or immunotherapy within 14 days before starting; the conditioning regimen is not counted. Other trial drugs to prevent graft-versus-host disease and herbal medicines are not allowed.
- Biomarker or test result
- Negative tests for HIV, hepatitis C and active hepatitis B. People with HIV on effective treatment and an undetectable viral load within 6 months can join. A tuberculosis test is required.
Main reasons for not taking part
- Earlier allogeneic stem cell transplant
- Pregnant or breastfeeding
- Active infection not responding to antibiotics
- Other active cancer that could affect the trial results
- Not expected to be available for follow-up for at least 100 days after the transplant
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Documented informed consent of the participant and/or legally authorized representative; Assent, when appropriate, will be obtained per institutional guidelines
- Agreement to allow the use of archival tissue from diagnostic tumor biopsies; If unavailable, exceptions may be granted with study principal investigator (PI) approval
- Age: ≥ 18 and ≤ 80 years old; Note: Patients > 70 years of age must have Karnofsky performance status ≥ 80 and hematopoietic cell transplantation-comorbidity index (HCT-CI) ≤ 2
- Karnofsky performance status ≥ 70%
- Patients with the following diagnosis, eligible to undergo allogeneic HCT from an 8/8 match related/unrelated donor (A, B, C, DR by high resolution typing); Acute Leukemias (acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL]) in complete remission with bone marrow (BM) blast of < 5%; Myelodysplastic syndrome (blast < 10%); Myeloproliferative neoplasm (MPN) other than myelofibrosis (MF) needing HCT; Chronic myelomonocytic leukemia (CMML)
- Hemoglobin ≥ 9g/dL (within 30 days prior to day 1 of protocol therapy); NOTE: Red blood cell transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement
- Total bilirubin ≤ 2.0 mg/dL (unless has Gilbert's disease) AND serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) < 5 times the upper limit of normal (ULN) (within 30 days prior to day 1 of protocol therapy)
- Aspartate aminotransferase (AST) =< 3.0 x ULN (within 30 days prior to day 1 of protocol therapy)
- Alanine aminotransferase (ALT) =< 3.0 x ULN (within 30 days prior to day 1 of protocol therapy)
- Creatinine clearance of ≤ 1.5 mg/dL or ≥ 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (within 30 days prior to day 1 of protocol therapy)
- Left ventricular ejection fraction (LVEF) ≥ 50%; Note: To be performed within 28 days prior to day 1 of protocol therapy
- IF ABLE TO PERFORM PULMONARY FUNCTION TESTS: Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and DLCO (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin); Note To be performed within 28 days prior to day 1 of protocol therapy
- IF UNABLE TO PERFORM PULMONARY FUNCTION TESTS: Oxygen (O2) saturation > 92% on room air; Note To be performed within 28 days prior to day 1 of protocol therapy
- Seronegative for HIV antigen/antibody (Ag/Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative) (within 30 days prior to day 1 of protocol therapy); HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- Tuberculosis test (within 30 days prior to day 1 of protocol therapy); Patients with positive tuberculosis (TB) test results will have infectious disease (ID) evaluation and post HCT therapy with isoniazid (INH) for 6 months with ID follow up. Vaccinated patients will need negative chest X-ray results
- Meets other institutional and federal requirements for infectious disease titer requirements; Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
- Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test (within 30 days prior to day 1 of protocol therapy); If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy; Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
Who cannot take part
- Prior allogeneic HCT
- Chemotherapy, radiation therapy, biological therapy, immunotherapy within 14 days prior to day 1 of protocol therapy; Note: Conditioning regimen within 14 days prior to day 1 of protocol therapy is not considered as an exclusion criterion. Patients on maintenance chemotherapy with agents listed are not excluded
- Other investigational drugs for GVHD prophylaxis
- Herbal medications
- Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients not expected to be available for follow-up in our institution for at least 100 days after the transplant
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent
- Clinically significant uncontrolled illness
- Active infection not responding to antibiotics
- Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
- Females only: Pregnant or breastfeeding
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- City of Hope Medical CenterDuarte, United StatesContact: Monzr M. Al MalkiTaking people
About the trial
What the trial wants to find out
This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a donor. Giving reduced conditioning chemotherapy before an allogeneic HCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new stem cells to grow using less than standard doses of chemotherapy. Sometimes, the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Vedolizumab is a monoclonal antibody, which is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). It may reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus suppresses the immune system by preventing the activation of certain types of immune cells. Giving vedolizumab plus PTCy and short course tacrolimus may be effective at preventing GVHD after allogeneic HCT.
The group in the trial
- Prevention (vedolizumab, cyclophosphamide, tacrolimus)Treatment being tested
Patients receive reduced intensity conditioning with fludarabine IV on days -7 to -3 and melphalan IV on day -2. Patients then undergo allogeneic HCT on day 0. Patients also receive vedolizumab IV over 30 minutes on days -1, +13, +41, +69, +97, +125, and +153, cyclophosphamide IV on days +3 and +4, and tacrolimus IV or PO on day +5 to day +95 in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT and ECHO or MUGA during screening, blood sample collection on study, and bone marrow biopsy throughout the study.
Treatment: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Melphalan, Multigated Acquisition Scan, Questionnaire Administration, Tacrolimus, and Vedolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase-2 Study of Vedolizumab Plus Post-Transplant Cyclophosphamide and Short Course Tacrolimus for Graft-versus-Host Disease Prevention After Reduced Intensity Conditioning Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplantation
- Plain-language title
- Tests vedolizumab with transplant drugs to prevent graft versus host diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06815003, who can take part
- Record updated
- 29 June 2026